文献速递烧伤创面修复瘢痕与激光

人脐带间充质干细胞与MEEK微移植联合移植兔模型长期自身对照研究

Combined transplantation of human umbilical cord mesenchymal stem cells and MEEK micrografts in rabbits: A long-term self-controlled study.
PubMed 文献 · Burns · 2026-02-03

本研究在兔背侧全层皮肤缺损模型上,将1×10⁷人脐带间充质干细胞(UCMSCs)经局部透明质酸凝胶或筋膜下注射与高扩张比(1:6)MEEK微移植联合应用。结果显示UCMSCs组上皮化速率加快、完全上皮化时间缩短,组织学上促进近正常再生并抑制纤维化,提示该策略对大面积烧伤有潜力。

要点

  • UCMSCs联合MEEK微移植可加速上皮化并缩短完全上皮化时间。
  • UCMSCs促进皮肤附属器再生、改善表皮/真皮结构并减轻炎症。
  • UCMSCs抑制纤维化,降低胶原容积分数及I/III型胶原比值。

核心结论

  • 局部或筋膜下UCMSC治疗可显著加速MEEK微移植后上皮化并抑制瘢痕增生,机制涉及促进再生、胶原正常化及抑制肌成纤维细胞/增殖/血管生成。

研究设计与样本

  • 兔自身对照研究,每只兔4个背侧全层皮肤缺损创面(n=13),随机接受四种治疗:A局部HA凝胶+1×10⁷ UCMSCs;B仅局部HA凝胶;C筋膜下生理盐水注射+1×10⁷ UCMSCs;D仅筋膜下生理盐水。
  • 评估指标包括上皮化速率、完全上皮化时间(CET)及愈合后0、1、2个月的组织学/免疫组化分析(H&E、Masson三色、天狼星红、α-SMA、Ki67、CD31)。

主要发现

  • UCMSC组(A、C)较对照组(B、D)愈合加速:术后第10天上皮化率A为62.0±5.8% vs B为56.8±6.2%(P=0.014);C为68.0±10.8% vs D为59.2±9.0%(P=0.033)。
  • 完全上皮化时间缩短:A为24.5±8.8天 vs B为29.0±7.9天(P=0.013);C为27.2±8.0天 vs D为31.5±10.9天(P=0.032)。
  • 组织学显示UCMSCs促进近正常再生(皮肤附属器增多、表皮/真皮结构改善、炎症减轻)并抑制纤维化(胶原容积分数及I/III型胶原比值降低,P<0.05)。
  • 免疫组化证实肌成纤维细胞活化减少(α-SMA,P<0.05),微血管密度(CD31⁺,术后第70/94天P<0.05)及增殖细胞(Ki67⁺,术后第70/94天P<0.05)降低。

临床怎么用

  • 对于大面积烧伤需高扩张比MEEK微移植的创面,可考虑联合局部或筋膜下注射1×10⁷ UCMSCs以加速上皮化并减轻瘢痕。
  • UCMSCs联合MEEK微移植可能通过促进再生、胶原正常化及抑制肌成纤维细胞/血管生成来改善愈合质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the efficacy of human umbilical cord mesenchymal stem cells (UCMSCs) in wound healing and scar formation following high-expansion (1:6) MEEK micrografting in rabbits. METHODS: Four dorsal full-thickness wounds per rabbit (n = 13) received randomized treatments: (A) topical hyaluronic acid (HA) gel + 1 × 10⁷ UCMSCs; (B) topical HA gel only; (C) subfascial normal saline (NS) injection + 1 × 10⁷ UCMSCs; (D) subfascial NS only. Assessments included epithelialization rate, complete epithelialization time (CET), and histological/immunohistochemical analysis (H&E, Masson richrome, Sirius Red, α-SMA, Ki67, CD31) at 0, 1, and 2 months post-healing. RESULTS: UCMSC groups (A, C) showed significantly accelerated healing vs controls (B, D): higher epithelialization rates at post-operative day (POD) 10 (A: 62.0 ± 5.8 % vs B: 56.8 ± 6.2 %, P = 0.014; C: 68.0 ± 10.8 % vs D: 59.2 ± 9.0 %, P = 0.033). Reduced CET (A: 24.5 ± 8.8 d vs B: 29.0 ± 7.9 d, P = 0.013; C:27.2 ± 8.0 d vs D: 31.5 ± 10.9 d, P = 0.032). Histology demonstrated UCMSCs promoted near-normal regeneration (increased skin appendages, improved epidermal/dermal organization, reduced inflammation) and inhibited fibrosis (lower collagen volume fraction and type I/III ratio, P < 0.05). Immunohistochemistry confirmed reduced myofibroblast activation (α-SMA, P < 0.05), microvascular density (CD31⁺, P < 0.05 at POD 70/94), and proliferative cells (Ki67⁺, P < 0.05 at POD 70/94). CONCLUSION: Topical or subfascial UCMSC therapy significantly accelerates epithelialization and inhibits scar hyperplasia post-MEEK micrografting through regenerative promotion, collagen normalization, and suppression of myofibroblasts/proliferation/angiogenesis, offering a promising strategy for extensive burns.

来源:Burns,查看原文。版权归原作者所有。

引用

  1. Xiao R, Yan T, Lin G, et al. Combined transplantation of human umbilical cord mesenchymal stem cells and MEEK micrografts in rabbits: A long-term self-controlled study. Burns. 2026. PMID: 41707535. doi:10.1016/j.burns.2026.107906

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。